Advanced Microsponge-Based Drug Delivery for Chronic Disease Management

Advanced drug delivery systems are gaining increasing relevance in healthcare, particularly for the treatment of chronic diseases, where sustained therapeutic efficacy, reduced dosing frequency, and improved patient adherence are critical unmet needs. Conventional formulations often fail to provide adequate control over drug release, stability, and local bioavailability, limiting their long-term effectiveness and translational impact.

Nanofaber’s research and innovation activities address these challenges through the development of nanostructured biomaterial-based delivery platforms, with a focus on MICROSPONGE technology based on hyaluronic acid and other biocompatible polymers. These systems are designed to enable prolonged release of therapeutic agents, and support localised treatment strategies in chronic inflammatory, ophthalmic, and degenerative conditions.

Nanofaber combines biomaterial engineering, pharmaceutical technology, and preclinical-oriented development, integrating formulation design, physicochemical characterisation, and translational considerations, including scale-up and regulatory readiness. Ongoing collaborative research with academic partners further supports optimisation and validation of these platforms.

We look for opportunities to join or build collaborative consortia within Horizon Europe Cluster calls, particularly in topics related to enabling technologies, nanotherapeutics, biomaterials, and chronic disease management, contributing as an industrial technology provider to multidisciplinary research and innovation projects.